Business Assessment

CryoMedic Technologies Blood Process Management System

About the Technology

The shelf life of blood is currently 42 days. CryoMedic Technologies has developed a new technology to economically and dramatically further extend the shelf life of blood — the end result of which is saving lives. This new technology will address the problems of blood management and safety on a global scale.

CryoMedic Technologies has the technology to cryogenically freeze blood. This new technology has the potential to revolutionize the global blood markets by changing the entire dynamic of how whole blood and platelet blood is drawn, stored, managed and dispensed. Because blood is a fragile biological component, the time element regarding its management is critical to its safety and usability. Cryogenically frozen blood (CFB) effectively eliminates time as an issue. CFB has an infinite shelf life. This makes managing its inventory incredibly efficient. Governments and Global Blood Organizations like the Red Cross, World Health Organization, etc. can more easily regulate donations of blood without fear of losing any supply due to time constraints. The global imbalance between demand and supply of blood can more easily be addressed among and between nations. Because blood can be stored ad infinitum, blood shortages can be permanently eliminated and the blood demand caused by world disasters and other factors can more readily be met. In short, blood supply and blood demand can be managed much more efficiently on a global scale. This will save untold numbers of lives and secure the safety of blood in ways unavailable until now.  

 

About the Process

CryoMedic Technologies currently has a patent pending which utilizes a unique variable heat transfer technique that addresses both freezing at -196°C and thawing at ambient room temperature. A plastic bag material, the CryoBlood Pak® (FDA approved) is used to contain the blood during the process. There is also a patent pending fabrication technique for the container bag.

This technique minimizes the red cell hemolysis normally caused by ice crystals puncturing the red cell walls, leaving resulting red cell recovery levels high enough to be acceptable by governing agencies for transfusion back into humans after storing for many years at approximately -196°C

A glycerol cryogenic protectorant is added to the blood prior to freezing. This material is washed out of the blood after thawing and prior to transfusion.

The basic research has been completed. Continuing clinical testing is in proces

 

Statistics on Blood

We have recently discovered that the Red Cross alone draws 14,000,000 bags of blood per year. Worldwide there are 93,000,000 (World Health Organization) bags of blood drawn annually at a cost of $200/ea. — with a shelf life of only 90 days. This technology will extend the shelf life of blood indefinitely, thereby eliminating inventory short falls and reducing the cost significantly.

Preliminary data shows that 45-50% of blood is lost due to shelf life. Currently, there are 14 million blood bags in the US an 1.5 million in Canada alone.

 

Funding

Interested investors should contact Jimmy Walker phone at 617-799-4211 or email for more detailed information.